Tickertape - Financial freedom begins here

Revenue from operations declined 5.55% YoY to Rs 8,070.5 crore in the quarter ended 30 June 2026. Profit before tax (PBT) dropped 70.98% YoY to Rs 552.6 crore in Q1 FY27. EBITDA slipped 55.72% to Rs 1,008.8 crore in Q1 FY27 compared with Rs 2,278.4 crore in Q1 FY26. EBITDA margin contracted to 12.5% in Q1 FY27 as against 26.7% in Q1 FY26. Revenue from the Global Generics segment declined 4.79% year-on-year to Rs 7,199.3 crore during the quarter. Revenue from the North America business fell 35.38% YoY to Rs 2,204.8 crore, mainly due to lower sales of Lenalidomide. The company launched six new products in the region during the quarter. Revenue from the India business increased 16.76% YoY to Rs 1,717.7 crore, supported by new brand launches, including innovative assets and recently acquired portfolios, along with price increases and higher sales volumes. The company launched seven new brands during the quarter. Revenue from the Europe region grew 13.30% YoY to Rs 1,444 crore, aided by the launch of 24 new generic products. The Emerging Markets segment reported a 30.52% YoY growth in revenue to Rs 1,832.8 crore, driven by new launches, higher volumes and favourable foreign exchange movement. Research and Development (R&D) expenditure stood at Rs 580 crore in Q1 FY27, down 8% year-on-year but up 6% sequentially. R&D expenses accounted for 7.1% of revenue during the quarter, compared with 7.3% in Q1 FY26. The decline was primarily due to lower development spending on biosimilars, while investments remained focused on complex generics, including peptides and biosimilars. Co-Chairman & MD, G V Prasad, said: Our Q1 FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide API. However, our underlying base business continued to deliver healthy doubledigit growth across all key geographies. Our focus remains on improving the health of our base business through disciplined execution and operational excellence, while building our future pipeline of peptides, biosimilars, and innovative assets to deliver long-term growth. Meanwhile, the company's board approved the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel and her induction as a member of the Management Council, effective 22 July 2026. Hyderabad-based Dr Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The scrip slipped 1.95% to settle at Rs 1,183 on the BSE. Powered by Capital Market - Live

Apollo Micro Systems has been shortlisted and awarded a Make-II Prototype Sanction Order (PSO) by the Indian Navy, in recognition of the Company's established capabilities in indigenous Naval Maritime Electronic Warfare. The project pertains to the design, development, and prototype demonstration of the Semi-Submersible Autonomous Vessel for Intelligence, Operations and Reconnaissance (SAVIOR-ASW) under the Make-II category. SAVIOR-ASW is an unmanned, semi-submersible maritime platform designed for persistent Anti-Submarine Warfare (ASW) surveillance, capable of autonomous operations for extended durations using advanced acoustic sensors, AI/ML-based target classification, and encrypted multi-channel communication systems. The system represents a significant step forward in India's indigenous underwater warfare capability. This is a prestigious and landmark order for the Company marking its formal entry into the domain of autonomous maritime and underwater warfare systems. In accordance with the Make-II category, there is no cost obligation on the Government during the prototype development phase. The Government is committed to procurement upon successful demonstration of the prototype.

The board of SRF at its meeting held on 22 July 2026 has approved the proposal to set up a BOPET Thick Film Line at a projected cost of Rs. 250 crore.

Shyam Metalics & Energy has fixed 07 August 2026 as record date for final dividend for FY 2025-26.

Azad Engineering delivers its First Expendable Indigenous Turbo jet Engine to DRDO (Defence Research and Development Organisation) and the Ministry of Defence, Government of India after Manufacturing and Assembly of Engine Components.

Hindustan Zinc announced that Crisil ESG Ratings & Analytics (Crisil ESG Ratings), a SEBI registered ESG Rating Provider, has independently and voluntarily assigned the Company an Environmental, Social & Governance rating as 'Crisil ESG 62' under category Strong.

The board of SunRisers Leeds (SRL) (Previously known as Northern Superchargers), a wholly owned subsidiary of Sun TV Network, at its meeting held on 21 July 2026, has approved a bonus issue of 99,999 equity shares of face value of 1 GBP each to Sun TV Network. Post completion of bonus issue, Sun TV Network will hold 1,00,000 equity shares of face value of 1 GBP each in SRL. There will be no change in the percentage of shareholding of the company in SRL. It will continue to remain a wholly owned subsidiary of the Company.

IIFL Finance has re-purchased at premium and settled USD 1,369,526.04 (which includes accrued interest) out of the total principal outstanding amount of USD 413,325,000 Senior Secured Fixed Rate Notes due 2028 (Notes) issued under Regulation S and Rule 144A of the U.S. Securities Act 1933. The re-purchase of the Notes are in compliance with the applicable laws including the Foreign Exchange Management (Borrowing and Lending) Regulations, 2018, read together with the Reserve Bank of India Master Direction - External Commercial Borrowings, Trade Credits and Structured Obligations and Foreign Exchange Management (Borrowing and Lending) (First Amendment) Regulations, 2026 as amended and updated from time to time, issued by Reserve Bank of India and was within the limit as approved by Authorised Dealer bank (AD - Bank).

Emcure Pharmaceuticals announced that it has completed the acquisition of 663,865 equity shares constituting 12.05% of balance equity share capital of Gennova Biopharmaceuticals (Gennova) for an aggregate consideration of Rs231.87 crore. With this acquisition, Gennova has become a wholly owned subsidiary of the company.

The board of HEG at its meeting held on 22 July 2026 has noted that the Company has applied to the Ministry of Corporate Affairs (MCA) for reservation of the proposed name HEG Advanced Materials in connection with the proposed change of its name from HEG Limited and the proposed name has been reserved by the Ministry of Corporate Affairs for a period of 60 days from the date of its approval. While the Company's post-restructuring focus was earlier described broadly as Greentech, the management has re-evaluated its long-term strategy to better align with the Company's core strengths in advanced manufacturing, specialized capabilities and value-added materials. The proposed name is intended to more accurately reflect the Company's business, strategic direction and corporate identity to its customers, investors and other stakeholders globally. In terms of Clause 27 of the Composite Scheme of Arrangement, the proposed change of name is conditional upon, and shall become effective concurrently with, the Scheme becoming fully effective. Upon the Scheme becoming effective, the Company shall undertake the necessary statutory and regulatory compliances for effecting the change of its name from HEG to HEG Advanced Materials and shall make the requisite disclosures to the Stock Exchanges in accordance with applicable laws.